The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback